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ABSTRACT
Background: Artificially sweetened beverages (ASBs) are com-
monly consumed and recommended for individuals at high risk for
cardiometabolic diseases; however, the health effects of ASBs re-
main contradictory. Given that cross-sectional analyses are subject to
reverse causation, prospective studies with long-term follow-up are
needed to evaluate associations between ASBs and cardiometabolic
health, especially among high-risk individuals.
Objective:The aim of this studywas to examine associations of ASB
intake and cardiometabolic health among high-risk womenwith prior
gestational diabetes mellitus (GDM).
Methods: We included 607 women with GDM from the Danish
National Birth Cohort (DNBC; 1996–2002) who completed a clinical
exam 9–16 y after the DNBC pregnancy for the Diabetes &Women’s
Health (DWH) Study (2012–2014). We assessed ASB intake using
FFQs completed during the DNBC pregnancy and at the DWH
Study clinical exam. We examined cardiometabolic outcomes at
the DWH clinical exam. We estimated percentage differences in
continuous cardiometabolic markers and RRs for clinical endpoints
in association with ASB intake both during pregnancy and at
follow-up adjusted for prepregnancy BMI, diet, and lifestyle factors.
Sensitivity analyses to account for reverse causation were performed.
Results: In pregnancy and at follow-up, 30.4% and 36.4% of
women regularly (≥2 servings/wk) consumed ASB, respectively.
Consumption of ASBs, both during pregnancy and at follow-up,
was associated with higher glycated hemoglobin (HbA1c), insulin,
HOMA-IR, triglycerides, liver fat, and adiposity and with lower
HDL at follow-up. After adjustment for covariates, particularly
prepregnancy BMI, the majority of associations between ASB
intake in pregnancy and outcomes at follow-up became null with
the exception of HbA1c. ASB intake at follow-up (≥1 serving/d
compared with <1 serving/mo) was associated with higher HbA1c
(6.5%; 95% CI: 1.9, 11.3; P-trend = 0.007); however, associations
were not upheld in sensitivity analyses for reverse causation.
Conclusions: Among Danish women with a history of GDM, ASB
intake was not significantly associated with cardiometabolic profiles.
Am J Clin Nutr 2019;110:221–232.
Keywords: artificially sweetened beverages, nonnutritive sweeten-
ers, soda, diet, obesity, diabetes, cardiometabolic health, gestational
diabetes
Introduction
Artificially sweetened beverages (ASBs) are commonly con-
sumed, with consumption increasing during the past decade in
western European countries (1). ASBs have been purported as
a low-calorie, healthier alternative to sugar-sweetened beverages
and recommended for individuals at high risk for cardiometabolic
diseases (2). Yet, scientific evidence on the short- and long-
term health effects of ASBs remains conflicting. Many, but not
all, animal studies suggest potential adverse effects of high
doses of nonnutritive sweeteners on glucose intolerance, insulin
resistance, and obesity that may be mediated through disruption
of homeostatic metabolic systems via activation of sweet taste
receptors and disruption of gut microbiota (3, 4). Well-designed
randomized controlled trials on long-term impacts of nonnutritive
sweeteners are sparse and generally have not observed beneficial
or adverse effects on body weight overall (5–7), although
there may be a benefit on body weight among overweight
or obese individuals (6). Last, observational studies show
potentially adverse associations with long-term consumption
of nonnutritive sweeteners, reporting higher body weight and
Am J Clin Nutr 2019;110:221–232. Printed in USA. Published by Oxford University Press on behalf of the American Society for Nutrition 2019. This work is
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risk for cardiometabolic complications (5). Of particular note,
findings from cross-sectional observational studies on ASBs
and cardiometabolic health may be subject to reverse causation
because individuals with an increased propensity for, or with,
cardiometabolic complications or overweight/obesitymay switch
to foods and beverages containing nonnutritive sweeteners with
the goal of reducing sugar intake.
In the current study, we aimed to examine associations of ASB
consumption on a comprehensive panel of cardiometabolic mark-
ers among Danish women with prior gestational diabetes mellitus
(GDM). This analysis addresses critical data gaps by examining
ASB consumption collected twice over 9–16 y, by including a
wide range of cardiometabolic endpoints, and by focusing on a
high-risk population (8). Women with a history of GDM (i.e.,
hyperglycemia first recognized in pregnancy) have a high risk for
developing type 2 diabetes (T2DM) and other cardiometabolic
complications, such as cardiovascular disease and nonalcoholic
fatty liver disease, later in life (9–11) and are therefore a good
model for evaluating ASB intake in a high-risk population. We
hypothesized that consumption of ASBs would be associated
with poor cardiometabolic health in women with prior GDM.
Methods
Study population
This study utilized data from Danish women enrolled in the
Diabetes & Women’s Heath (DWH) Study (12), a long-term
follow-up of women with GDM during the index pregnancy of
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the Danish National Birth Cohort (DNBC) (1996–2002) (13).
All women with GDM in the DNBC (n = 1274 out of 91,827
women) were invited to participate in the DWH Study (2012–
2014), of whom a total of 790 participated. The DWH Study
follow-up consisted of questionnaires and a clinical exam; the
clinical exam was completed by 607 women (Supplemental
Figure 1). In the DNBC, women were classified as having a
diagnosis of GDM if it was recorded in the Danish National
Patient Register or women reported having GDM on the DNBC
telephone interviews at 30 weeks of gestation or 6 mo postpartum
(14). Women who participated in the DWH Study were largely
comparable to the eligible source population with respect to age
(31.6 y in the DWH Study compared with 31.3 y in the source
population), prepregnancy BMI (in kg/m2; 27.5 compared with
27.7), nulliparity (54.9% compared with 56.7%), and smoking
status (26.4% compared with 28.4%).
All women provided written informed consent. The study
was approved by the Regional Scientific Ethical Committee
of the Capital Region of Denmark (record no. H-4-2013-129).
The Strengthening the Reporting of Observational Studies in
Epidemiology cohort reporting guidelines were followed (15).
The primary aim of the DWH Study was to identify genomic
and environmental determinants underlying the development of
T2DM and comorbidities among women with a history of GDM.
The aims were not changed during the course of the study.
The current analysis was not prespecified and is considered
exploratory.
Exposure measures
Dietary intake was assessed at 2 time points: 1) during
pregnancy during the conduct of the DNBC and 2) 9–16 y later
as part of the DWH Study follow-up. Diet during the index
pregnancywas assessed at 25weeks of gestation using a validated
semiquantitative 360-item FFQ, which collected information
on habitual dietary intake during the previous month (16–18).
Overall, the FFQ response rate in the DNBC was 74.2% (16),
and the reliability of self-reported ASB intake assessed twice in
a subsample was high (19). Similar to prior studies, dietary data
for women with implausible daily energy intake (<956 or>4780
kcal/d; n = 4) were excluded (20). Diet at the follow-up clinical
exam was assessed using a similar semiquantitative 360-item
FFQ that collected information on habitual dietary intake during
the previous year. Dietary data for women with implausible daily
energy intake (<600 or >4000 kcal/d; n = 19) were excluded
(21). Different cutoffs for implausible energy intake were applied
to DNBC and the DWH Study because 1 represented a pregnant
population and the other a nonpregnant population. A total of 438
(72.2%) women had complete dietary data at both time points.
Missing dietary data were imputed as described later.
For both DNBC and DWH dietary data, a variable for
total ASB intake was created by summing carbonated and
noncarbonated sources of ASB. Specifically, on the DNBC FFQ,
individuals reported intake of “Soda pop/CocaColawithout sugar
(diet)” and “Lemonade without sugar (diet)” using 11 categories
of intake ranging from “None per month” to “8 or more per
day.” On the DWH FFQ, individuals reported their intake of
“Soft drink and Coke, light (no sugar)” and “Lemonade, light (no
sugar)” using 12 categories ranging from “Never during the last
year” to “8 or more times per day.” For both time points, based
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on assumptions on standard portion sizes, reported frequency of
intake was converted to grams/day using the FoodCalc program
(22) combined with the Danish Food Composition Database
(23). Servings per day of ASB were estimated based on the
assumption that 1 serving was equivalent to 250 grams (20).
Dietary data at both time points were utilized to calculate
the Alternate Healthy Eating Index (AHEI) to assess overall
dietary quality. The AHEI includes the following components:
vegetables, fruits, whole grains, sugar-sweetened beverages, nuts
and legumes, red/processed meat, trans fat, long-chain (n–3) fats
(EPA + DHA), PUFAs as percentage of energy, sodium, and
alcohol (24).
Outcome measures
Outcome measures were collected at follow-up clinical
exam according to a standardized protocol, which consisted of
anthropometric measurements; blood pressure measurements;
fasting blood samples; and a 2-h, 75-g oral glucose tolerance
test (in those without diabetes). Height (centimeters), weight
(kilograms), and waist circumference (centimeters) midway
between the lowest rib and the iliac crest were measured at least
twice. BMI was calculated. Mean resting arterial blood pressure
was calculated as [(systolic blood pressure) + 2 x (diastolic
blood pressure)]/3. A whole-body DXA (GE Lunar Prodigy; GE
Healthcare) scan was performed on a subset of women who
had their clinical exam performed at Rigshospitalet (n = 192).
Abdominal visceral adipose tissue mass was estimated using
enCORE software (version 15; GE Healthcare) (25). At follow-
up, women also self-reported heart disease, type 1 diabetes,
T2DM, cancer, gout, elevated cholesterol, and elevated blood
pressure.
Biospecimens were collected according to a standardized
protocol. Fasting plasma glucose (millimoles per liter) and
insulin (picomoles per liter) were measured immediately at the
clinic after an ∼8- to 10-h overnight fast; all other sample
aliquots were processed and immediately frozen at −80◦C for
assays at a later date. The following were measured in plasma
using Roche Diagnostics reagents with assay CVs ≤4% unless
otherwise noted: triglycerides (TGs; milligrams per decaliter),
total cholesterol (milligrams per decaliter), HDL (milligrams
per decaliter), alanine aminotransferase (ALT; international
units per liter), aspartate aminotransferase (AST; international
units per liter), γ -glutamyltransferase (international units per
liter), total bilirubin (milligrams per decaliter; CV <7.3%), C-
reactive protein–high sensitivity (CRP; milligrams per liter),
and C-peptide (nanomoles per liter; Quansys Biosciences; CV
<10.0%). LDL (milligrams per decaliter) was calculated as total
cholesterol – HDL – (TG/5). Glycated hemoglobin (HbA1c;
percentage; CV <1.2%) was measured in whole blood (Tosoh
Bioscience).
Insulin resistance was determined by calculating HOMA-IR
and homeostatic model assessment for β-cell function, which are
calculated as follows (26):
HOMA − IR = (fasting plasma insulin [mU/L]
×fasting plasma glucose [mmol/L])/22.5 (1)
HOMA − %B = (20 × fasting plasma insulin [mU/L])/
(fasting plasma glucose [mmol/L] − 3.5) (2)
Fatty liver was determined by calculating a liver fat score and
liver fat percentage. Although not directly assessed by imaging,
the liver fat score was previously validated for the prediction
of nonalcoholic steatohepatitis assessed using proton magnetic
resonance spectroscopywith a receiver operating characteristic––
AUC of 0.87 (95%CI: 0.83–0.90) (27). The liver fat score utilizes
the presence of metabolic syndrome (28) and T2DM and levels
of insulin, AST, and ALT; it is calculated as follows (27):
liver fat score = − 2.89 + 1.18
× metabolic syndrome (yes = 1/no = 0)
+ 0.45×T2DM (yes = 2/no = 0)
+ insulin (mU/L) + 0.04 × AST (U/L)
− 0.94 × AST/ALT (3)
Similarly, a previously validated continuous measure of liver fat
percentage was calculated as follows (27):
liver fat(%) = 10(−0.805+0.282
×metabolic syndrome(yes=1;no=0)+0.078
×T2DM(yes=2;no=0)+0.525×log(insulin [mU/L])
+0.521×log(AST[U/L])−0.454×log(AST/ALT)
)
(4)
Cardiometabolic endpoints included obesity (BMI ≥30.0),
hyperglycemia (fasting glucose ≥7.0 mmol/L), hypertriglyc-
eridemia (TG ≥200 mg/dL), T2DM, elevated liver function
markers AST:ALT ratio (ratio ≥2), ALT (≥19.0 U/L), and an
elevated liver fat score (> −0.640) (27). Diagnosis of T2DMwas
based on clinical exam results (HbA1c ≥6.5%, fasting glucose
≥7.0 mmol/L, or 2-h oral glucose tolerance test glucose ≥11.1
mmol/L) or self-report of physician diagnosis (29).
Additional variable measures
During the DNBC pregnancy, the following relevant variables
were collected: current age, prepregnancy BMI (continuous)
calculated from self-reported prepregnancy height and weight,
high school education (yes/no), nulliparity (yes/no), ever smoker
(yes/no), moderate or vigorous physical activity during preg-
nancy (minutes per week) (30), and prepregnancy chronic
diseases (yes/no) including hypertension and cancer (no women
had prepregnancy diabetes because the cohort consisted of all
women with GDM during the index pregnancy). Physical activity
was ascertained by asking women to report the types of exercise
in which they engaged and, when relevant, the frequency and
duration. The duration of moderate and vigorous activities was
summed.
In addition to the clinical exam outcomes described previously,
the following relevant variables were collected at the DWHStudy
follow-up: current age, employed (yes/no), high school education
(yes/no), current smoker (yes/no), and moderate or vigorous
physical activity (metabolic equivalent hours per week) (31).
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Statistical analyses
ASB intake was classified by frequency as <1/mo (reference),
1–4/mo, 2–6/wk, and ≥1/d to allow for similar categories across
the 2 time points, provide for public health relevant cut points, and
follow prior articles on beverage intake (21). Descriptive analyses
estimated the mean (SD) or median (IQR), as applicable, or
frequency of the discrete covariates within each category of ASB
exposure with statistical significance estimated using ANOVA or
Wilcoxon 2-sample test statistic or chi-square tests, respectively.
Models of continuous outcomes used log-transformed outcomes,
and the final results were presented as the percentage change
in each outcome. Models with binary clinical outcomes utilized
modified Poisson regression with robust variance to estimate
RRs and 95% CIs for each category of intake. A linear trend
test across categories was performed using the median value
within each category estimated as a continuous exposure. In order
to rule out fatty liver due to alcohol intake, all models with
liver-related outcomes (i.e., AST, ALT, γ -glutamyltransferase,
bilirubin, AST:ALT ratio, calculated liver fat percentage, and
elevated liver fat score) excluded women with high alcohol
consumption reported at the clinical exam (52.4%; >24 g/d,
approximately equivalent to 2 standard drinks/d) (32).
We used multiple imputation with 20 replicates to address
missing exposure and covariate data for women who participated
in the clinical exam (33, 34). We assumed that the data were
missing at random. Each missing variable was imputed using
dietary and covariate data at both time points (i.e., pregnancy and
follow-up) and the log-transformed continuous outcomes. The
distributions of the imputed variables were checked; the range of
the continuous values was limited to the range in the original data.
The first set of analyses examined the association of the DNBC
pregnancy ASB exposure with continuous cardiometabolic
markers and clinical outcomes at DWH follow-up. The following
covariates at the index pregnancy were selected a priori:
prepregnancy age (continuous), prepregnancy BMI (continuous),
nulliparous (yes/no), smoking (yes/no), moderate or vigorous
physical activity (continuous), prepregnancy chronic diseases
(yes/no), AHEI (continuous), coffee intake (continuous), and tea
intake (continuous). The AHEI was chosen as a covariate because
of its association with cardiometabolic disease (24). Because the
AHEI included sugar-sweetened beverages as a component, they
were not individually adjusted for in the analyses. We a priori
included coffee and tea as covariates because of their associations
with cardiometabolic health (35), and we hypothesized that
women may replace artificially or sugar-sweetened beverages
with either coffee or tea. Analyses were further adjusted for
BMI at the follow-up exam (continuous) in a second model.
Sensitivity analyses were performed stratifying by prepregnancy
BMI (<25.0 compared with ≥25.0) with the goal of reducing
the potential for reverse causality because the reason for ASB
consumption may differ between women with and those without
overweight or obesity.
The second set of analyses examined the association of
the DWH Study follow-up ASB exposure with continuous
cardiometabolic markers and clinical endpoints. Covariates
selected a priori included current age (continuous), prepregnancy
BMI at the index DNBC pregnancy (continuous), primiparous
(yes/no), smoking (yes/no), moderate or vigorous physical
activity (continuous), prepregnancy chronic diseases (yes/no),
AHEI (continuous), coffee intake (continuous), and tea intake
(continuous). To reduce the potential for residual confound-
ing and reverse causation, all analyses were adjusted for
prepregnancy BMI and the following sensitivity analyses were
performed. First, sensitivity analyses were performed stratifying
by prepregnancy BMI (<25.0 compared with ≥25.0) for 2
reasons: to further remove reverse causation and to further limit to
higher risk women. Second, we excluded women with prevalent
chronic diseases (i.e., self-reported type 1 or 2 diabetes, heart
problems, cancer, elevated cholesterol, elevated blood pressure,
or gout) at follow-up (n = 235). Third, we excluded women who
reported not consuming any ASBs in pregnancy (n = 249). The
latter 2 analyses were performed to further examine associations
with current consumption levels, reducing the likelihood that
women started consuming ASBs in response to an indication for
health problems.
The third set of analyses examined the longitudinal pattern
of ASB exposures by utilizing exposures both during pregnancy
and at follow-up 9–16 y after the index pregnancy. Women were
classified according to whether they consumed ASBs in the
lower 2 categories (≤4/mo; i.e., no consumption or occasional)
or the highest 2 categories (≥2/wk; i.e., regular consumption)
at each time point, with the reference being women with no or
occasional consumption at both time points. Covariates included
those described previously for the pregnancy exposure models.
Sensitivity analyses were performed stratifying by prepregnancy
BMI (<25.0 compared with ≥25.0) and limiting analysis to
women without chronic diseases at follow-up. At follow-up,
women were asked if they added artificial sweeteners to their
coffee or tea. Sensitivity analyses were performed combining
coffee and tea with ASB in cases in which artificial sweeteners
were added. Also, intake of artificial and sugar-sweetened
beverages tended to be inversely correlated in our data. Therefore,
we performed sensitivity analyses of ASB intake among women
consuming <1 serving per month of sugar-sweetened beverages
to fully remove any residual confounding. Last, sensitivity
analyses utilized stabilized inverse probability weights to account
for loss to follow-up.
All analyses were performed by using SAS software (version
9.4; SAS Institute), with P < 0.05 considered significant.
Results
During pregnancy, 30.4% (n = 139) of women reported
consuming ASBs regularly (i.e., ≥2 servings per week); at
the DWH Study follow-up 9–16 y later, 36.4% (n = 211) of
women reported consuming ASBs regularly. Notably, 62.7%
(n = 287) and 7.9% (n = 46) reported regular consumption
of sugar-sweetened beverages across the same time period,
respectively. Table 1 displays the participant characteristics
according to ASB intake in pregnancy and at the DWH Study
follow-up. Prepregnancy BMI increased significantly with higher
consumption of ASB, ranging from mean values of 26.0 among
women consuming <1 serving per month to 30.1 among women
consuming ≥1 serving per day.
Overall consumption of ASBs both during pregnancy (Table
2) and at follow-up (Table 3) was associated with less
favorable cardiometabolic profiles at follow-up. However, after
adjustment for covariates including prepregnancy BMI, only
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TABLE 1 Participant characteristics according to artificially sweetened beverage intake in pregnancy and at follow-up 9–16 y later among women with a
history of gestational diabetes1
Artificially sweetened beverage intake in pregnancy (1996–2002)2
<1 serving/mo 1–4 servings/mo 2–6 servings/wk ≥1 servings/d
Characteristics in pregnancy (1996–2002) (n = 205) (n = 72) (n = 121) (n = 60) P3
Age, y 31.6 (4.3) 32.1 (4.7) 31.0 (4.3) 31.3 (4.5) 0.38
Prepregnancy BMI, kg/m2 26.0 (5.5) 26.5 (5.2) 27.6 (5.0) 30.1 (6.2) <0.001∗
Nulliparous 120 (58.5) 42 (58.3) 64 (52.9) 35 (58.3) 0.96
High school education or greater 72 (35.1) 18 (25.0) 40 (33.1) 19 (31.7) 0.84
Smoker 49 (23.9) 17 (23.6) 33 (27.3) 20 (33.3) 0.43
Prepregnancy chronic diseases4 17 (8.3) 9 (12.5) 11 (9.1) 4 (6.7) 0.66
Moderate/vigorous physical activity,
MET-h/wk
0.0 (0.0, 30.0) 0.0 (0.0, 45.0) 0.0 (0.0, 30.0) 0.0 (0.0, 10.0) 0.76
Total energy, kcal/d 2458.7 (638.3) 2434.0 (598.3) 2351.3 (667.7) 2420.1 (622.6) 0.53
Coffee intake, g/d 13.4 (0.0, 150.0) 13.4 (0.0, 375.0) 0.0 (0.0, 150.0) 22.8 (0.0, 150.0) 0.78
Tea intake, g/d 32.1 (13.4, 150.0) 75.0 (13.4, 375.0) 32.1 (0.0, 150.0) 75.0 (6.7, 262.5) 0.39
Sugar-sweetened beverage intake, g/d 145.0 (72.3, 253.2) 102.4 (25.9, 203.0) 92.1 (27.1, 197.7) 70.5 (23.1, 234.6) <0.001∗
AHEI score5 47.9 (7.6) 50.0 (8.2) 49.5 (7.7) 48.3 (7.6) 0.13
Habitual artificially sweetened beverage intake at follow-up (2012–2014)6
<1 serving/mo 1–4 servings/mo 2–6 servings/wk ≥1 servings/d
Characteristics at follow-up (2012–2014) (n = 197) (n = 88) (n = 214) (n = 87) P3
Age, y 44.8 (4.9) 44.0 (4.9) 43.2 (4.3) 42.6 (3.8) <0.001∗
BMI, kg/m2 26.8 (5.2) 29.2 (5.6) 29.6 (6.0) 31.6 (5.6) <0.001∗
Primiparous 25 (17.1) 15 (13.1) 28 (16.1) 14 (0.0) 0.71
High school education 197 (86.8) 88 (83.0) 214 (83.6) 87 (81.6) 0.67
Smoker 34 (17.3) 11 (12.5) 42 (19.6) 18 (20.7) 0.44
Prevalent chronic diseases7 64 (32.5) 31 (35.2) 95 (44.4) 45 (51.7) 0.007∗
Moderate/vigorous physical activity,
MET-h
24.9 (10.8, 51.7) 22 (9.4, 56.8) 25 (8.6, 41.9) 16.5 (7.9, 40.0) 0.14
Energy intake, kcal/d 1964 (613.4) 1904.9 (594.4) 1935.8 (515.1) 1852.5 (600.2) 0.48
Coffee intake, g/d 169.9 (11.9, 487.8) 145.8 (15.5, 469.8) 165.1 (9.7, 410.6) 12.5 (0.0, 375) <0.001∗
Tea intake, g/d 48.1 (9.3, 226.7) 48.8 (10.6, 225) 38.9 (3.3, 200) 33.6 (3.3, 200) 0.21
Sugar-sweetened beverage intake, g/d 8.3 (4.3, 25.3) 16.9 (5.9, 20.3) 5.4 (1.6, 21.4) 4.6 (1.0, 12.7) <0.001∗
AHEI score5 52.4 (9.9) 52.7 (9.8) 50.9 (8.9) 50.0 (9.2) 0.09
1Data presented as mean (SD), median (IQR), or n (%), as applicable. ∗Statistical significance, P < 0.05. AHEI, Alternative Healthy Eating Index–2010; MET-h, metabolic
equivalent hours.
2Characteristics not shown for the 149 women missing artificially sweetened beverage intake in pregnancy.
3P values for parametric continuous variables calculated using ANOVA; P values for nonparametric continuous variables calculated using Wilcoxon 2-sample test statistic;
and P values for categorical variables calculated using chi-square test statistic or Fisher’s exact test, as applicable.
4Prepregnancy chronic diseases include cancer and hypertension; no women had prepregnancy diabetes because the cohort consisted of all women with gestational diabetes
during the index pregnancy.
5AHEI score includes vegetables, fruit, whole grains, sugar-sweetened beverages and fruit juice, nuts and legumes, red/processed meat, trans-fat, long-chain (n–3) fats
(EPA + DHA), PUFAs, sodium, and alcohol.
6Characteristics not shown for the 28 women missing artificially sweetened beverage intake at follow-up.
7The definition of prevalent chronic diseases was based on self-report of ever having a physician diagnosis of the following conditions: type 1 or type 2 diabetes, heart
problems, cancer, gout, elevated cholesterol, or elevated blood pressure.
women consuming ASBs weekly or daily in pregnancy had
HbA1c levels that were 3–4% higher than in women consuming
ASBs <1 serving per month (P-trend = 0.06); findings on other
cardiometabolic phenotypes (e.g., insulin, C-peptide, HOMA-IR,
waist circumference, hypertriglyceridemia, and obesity) either
did not follow a significant trend with higher consumption or
were not observed in the highest intake level (Table 4). When
limited towomenwith normal weight before the index pregnancy,
a significant trend (P = 0.01) was observed with higher ASB
intake and HbA1c, such that daily intake was associated with
9.9% higher levels (95% CI: 1.2, 19.3) (Supplemental Table
1); however, among women with prepregnancy overweight or
obesity, no significant trends were observed, and the majority
of associations were null with the exception of higher C-
peptide and liver fat percentage levels and an increased risk for
elevated triglycerides among monthly consumers compared to
nonconsumers (data not shown).
After adjusting for confounding variables including prepreg-
nancy BMI, habitual ASB intake in the past year was not
associated with the majority of cardiometabolic markers or
clinical outcomes at follow-up except for ∼3–7% higher HbA1c
levels among women consuming ASBs at least weekly compared
to those consuming ASBs <1 serving per month (Table 5).
When limited to women with prepregnancy normal weight, the
significant trend with HbA1c was maintained, and an increased
risk of hyperglycemia was also observed (Supplemental Table
2). Among women with prepregnancy overweight or obesity, no
significant trends were observed, and the majority of associations
were null with the exception of lower LDL levels among
monthly and weekly consumers and a lower AST:ALT ratio
among monthly consumers compared with nonconsumers (data
not shown). When limited to women who were consumers of
ASBs in pregnancy, the association with habitual intake in the
past year of the follow-up and HbA1c levels was consistently
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TABLE 2 Unadjusted cardiometabolic outcomes at follow-up 9–16 y later according to artificially sweetened beverage intake in pregnancy among women
with a history of gestational diabetes1
Artificially sweetened beverage intake in pregnancy (1996–2002)2
<1 serving/mo 1–4 servings/mo 2–6 servings/wk ≥1 servings/d
n (n = 205) (n = 72) (n = 121) (n = 60) P3
Continuous outcomes (2012–2014)
HbA1C, % 603 5.3 (5.1, 5.6) 5.5 (5.0, 5.7) 5.5 (5.2, 5.9) 5.5 (5.1, 5.9) 0.02∗
Fasting glucose, mmol/L 603 5.3 (5.0, 5.9) 5.5 (5.1, 6.1) 5.5 (5.0, 6.2) 5.6 (5.0, 6.4) 0.11
Fasting insulin, pmol/L 600 44.0 (31.0, 69.0) 51.5 (38.0, 82.0) 49.0 (36.0, 80.0) 60.5 (47.0, 92.0) <0.001∗
C-peptide, pmol/L 601 884.4 (686.4, 1221) 1062.6 (765.6, 1343.1) 983.4 (739.2, 1247.4) 1042.8 (811.8, 1234.2) 0.02∗
HOMA-IR 599 1.5 (1.0, 2.4) 1.9 (1.3, 3.3) 1.8 (1.2, 3.1) 2.3 (1.5, 3.3) <0.001∗
HOMA-B 599 63 (45.5, 101.2) 78 (51.3, 108.8) 75.1 (48.7, 101.7) 85.6 (61.7, 112.9) 0.04∗
Triglycerides, mg/dL 601 95.0 (73.0, 135.0) 107.5 (80.5, 159.0) 109.0 (85.0, 148.0) 112.0 (91.0, 172.0) 0.01∗
HDL, mg/dL 601 59.0 (49.0, 71.0) 58.0 (48.5, 69.5) 55.0 (47.0, 68.0) 53.0 (46.0, 61.0) 0.04∗
LDL, mg/dL 592 113.0 (96.0, 135.0) 116.0 (90.0, 144.0) 113.0 (98.0, 133.0) 110.0 (84.0, 137.0) 0.78
BMI, kg/m2 606 26.7 (23.7, 31.3) 27.7 (24.4, 31.6) 29.9 (26.1, 33.3) 30.8 (28.0, 34.3) <0.001∗
Waist circumference, cm 606 95.6 (87.0, 105.8) 98.3 (90.3, 106.8) 101.2 (91.5, 111.6) 104.4 (97.9, 115.7) <0.001∗
Visceral adipose tissue, cm3 192 624.0 (328.0, 1077.5) 824.0 (245.0, 1432.0) 771.0 (425.5, 1127.0) 800.0 (353.0, 1609.0) 0.48
Mean arterial pressure, mm Hg 607 89.8 (84.3, 101.2) 93.3 (85.8, 100.7) 91.3 (84.2, 101.2) 93.1 (85.5, 102.6) 0.65
CRP, mg/L 600 1.2 (0.6, 3.1) 1.7 (0.7, 3.6) 1.9 (0.7, 4.0) 1.8 (0.6, 5.4) 0.08
ALT, U/L4 284 19.0 (16.0, 24.0) 19.0 (15.0, 29.0) 20.0 (17.0, 26.0) 19.0 (14.5, 27.5) 0.78
AST, U/L4 283 27.5 (22.5, 33.5) 28.0 (24.0, 36.0) 30.0 (24.0, 34.0) 26.5 (20.0, 35.0) 0.52
AST:ALT ratio4 283 1.4 (1.2, 1.8) 1.5 (1.3, 1.8) 1.4 (1.1, 1.6) 1.4 (1.2, 1.6) 0.27
Liver fat, %4,5 280 2.5 (1.9, 5.4) 2.6 (1.7, 7.3) 3.8 (2.1, 8.0) 5.0 (2.4, 7.5) 0.04∗
GGT, U/L4 286 17.0 (12.0, 28.0) 16.0 (13.0, 30.0) 18.0 (13.0, 30.0) 22.0 (15.0, 35.0) 0.27
Bilirubin, mg/dL4 285 0.4 (0.3, 0.5) 0.3 (0.3, 0.5) 0.3 (0.2, 0.4) 0.3 (0.3, 0.5) 0.15
Binary outcomes at follow-up (2012–2014)6
Hyperglycemia 603 18 (8.8) 10 (13.9) 16 (13.2) 8 (13.3) 0.48
Type 2 diabetes 607 45 (22.0) 22 (30.6) 33 (27.3) 20 (33.3) 0.23
Hypertriglyceridemia 601 13 (6.3) 13 (18.1) 11 (9.1) 6 (10.0) 0.04∗
Obesity 606 59 (28.8) 26 (36.1) 60 (49.6) 33 (55.0) <0.001∗
Elevated ALT 4 284 52 (56.5) 18 (52.9) 38 (57.6) 18 (52.9) 0.96
Elevated AST:ALT ratio4 284 12 (13.0) 6 (17.7) 4 (6.1) 4 (11.8) 0.35
Elevated liver fat score4,7 280 34 (37.0) 15 (44.1) 34 (51.5) 19 (55.9) 0.11
1Data presented as mean (SD), median (IQR), or n (%), as applicable. All values are unadjusted. ∗Statistical significance, P < 0.05. ALT, alanine aminotransferase; AST,
aspartate aminotransferase; CRP, C-reactive protein; fs, fasting serum; GGT, γ -glutamyltransferase; HOMA-B, homeostatic model assessment for β-cell function; T2DM, type 2
diabetes mellitus.
2Outcomes not shown for the 149 women missing artificially sweetened beverage intake in pregnancy.
3P values for parametric continuous variables calculated using ANOVA; P values for nonparametric continuous variables calculated using Wilcoxon 2-sample test statistic;
and P values for categorical variables calculated using chi-square test statistic or Fisher’s exact test, as applicable.
4Outcomes related to liver function exclude women with habitual alcohol intake at follow-up of >24 g/d, approximately equivalent to 2 standard drinks/d.
5Calculated liver fat % = 10(−0.805 + 0.282 × metabolic syndrome (yes = 1; no = 0) + 0.078 × T2DM (yes = 2; no = 0) + 0.525 × log(fs-insulin [mU/L]) + 0.521 × log(fs-AST [U/L]) – 0.454 × log(AST/ALT)).
6The following definitions were used for the binary outcomes: elevated ALT, ≥19.0 U/L; elevated AST:ALT ratio, ratio ≥2; elevated liver fat score, >−0.640;
hypertriglyceridemia, triglycerides ≥200 mg/dL; hyperglycemia, fasting glucose ≥7.0 mmol/L; type 2 diabetes, HbA1c ≥6.5%, fasting glucose ≥7.0 mmol/L, or 2-h oral glucose
tolerance test glucose ≥11.1 mmol/L or self-report of physician diagnosis; obesity, BMI ≥30.0.
7Liver fat score = −2.89 + 1.18 × metabolic syndrome (yes = 1/no = 0) + 0.45 × T2DM (yes = 2/no = 0) + insulin (mU/L) + 0.04 × AST (U/L) – 0.94 × AST/ALT.
observed (Supplemental Table 3). However, when limited to
women without known chronic diseases at follow-up, the results
were attenuated (Supplemental Table 4).
Between pregnancy and follow-up, more women regularly
consumed ASBs (30.4% compared with 36.4%), yet on average
the weekly intake did not differ among the regular consumers
[mean change: 0.2 servings per week (SD= 12.2);P= 89]. Com-
paratively, fewer women regularly consumed sugar-sweetened
beverages (62.7% compared with 7.9%), and among regular con-
sumers the average weekly intake also decreased [mean change:
−4.8 servings per week (SD = 9.0); P = 0.02]. Table 6 displays
associations between ASB consumption and cardiometabolic
outcomes according to women’s ASB consumption in pregnancy
and in the past year at the follow-up visit. Compared with women
with occasional or no consumption (i.e., ≤4 servings per month)
in pregnancy and at follow-up, women with regular consumption
(i.e., ≥2 servings per week) at both time points had 6–7% higher
HbA1c and fasting glucose levels and a 37% increased risk
in obesity. Among women with prepregnancy normal weight,
regular consumption at both time points was associated with
increased HbA1c, fasting glucose, triglyceride, and liver fat
levels (Supplemental Table 5). However, among women with
prepregnancy overweight or obesity (data not shown) or without
known chronic diseases at follow-up, the results were attenuated
(Supplemental Table 6).
Sensitivity analyses utilizing inverse probability weights to
account for loss to follow-up yielded similar results (data not
shown). At follow-up, 6.9% and 9.4% of women added artificial
sweeteners to their coffee and tea, respectively. Sensitivity
analyses that included servings of coffee and tea with added
artificial sweeteners to the ASB intake categories yielded similar
results to the overall findings, with only a significant trend
observed across ASB categories for HbA1c (Supplemental
Table 7). Last, sensitivity analyses limited to nonconsumers of
sugar-sweetened beverages in pregnancy (n = 82) or at follow-
up (n = 319) also yielded findings that were null but generally in
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TABLE 3 Unadjusted cardiometabolic outcomes at follow-up according to artificially sweetened beverage intake at follow-up among women with a history
of gestational diabetes1
Habitual artificially sweetened beverage intake at follow-up (2012–2014)2
n (n = 197) (n = 88) (n = 214) (n = 87) P3
Continuous outcomes (2012–2014)
HbA1c, % 603 5.4 (5.2, 5.6) 5.3 (5.1, 5.7) 5.5 (5.2, 5.9) 5.5 (5.2, 6.1) 0.003∗
Fasting glucose, mmol/L 603 5.4 (5.0, 5.9) 5.4 (5, 5.9) 5.5 (5.1, 6.2) 5.5 (5, 6.2) 0.08
Fasting insulin, pmol/L 600 44.0 (31.0, 68.0) 48.5 (36.0, 78.5) 52.0 (36.0, 80.0) 57.0 (43.0, 86.0) <0.001∗
C-peptide, pmol/L 601 891.0 (699.6, 1181.4) 973.5 (782.1, 1280.4) 970.2 (755.7, 1240.8) 1069.2 (844.8, 1221) 0.09
HOMA-IR 599 1.5 (1.0, 2.3) 1.6 (1.3, 2.7) 1.9 (1.2, 3.1) 2.1 (1.5, 3.6) <0.001∗
HOMA-B 599 66.0 (44.0, 96.8) 71.7 (54.1, 98.5) 73.9 (48.3, 105.2) 82.6 (58.5, 108.4) 0.13
Triglycerides, mg/dL 601 95.0 (72.0, 136.0) 93.5 (75.5, 133.5) 107.0 (84.5, 155.5) 116.0 (90.0, 173.0) <0.001∗
HDL, mg/dL 601 60.0 (50.0, 71.0) 59.0 (49.0, 70.0) 55.0 (47.0, 67.0) 54.0 (47.0, 62.0) 0.003∗
LDL, mg/dL 592 120.0 (97.0, 143.0) 107.5 (92.5, 128.0) 111.0 (94.0, 133.0) 114.0 (89.0, 134.0) 0.06
BMI, kg/m2 606 25.7 (23.1, 29.9) 29.2 (24.9, 33.3) 29.1 (25.4, 33.3) 31.4 (27.0, 34.9) <0.001∗
Waist circumference, cm 606 94.2 (86.3, 103.8) 99.5 (92.2, 111.9) 100.6 (90.6, 108.6) 105.1 (96.6, 114.3) <0.001∗
Visceral adipose tissue, cm3 192 692.0 (348.0, 1113.0) 677.0 (357.0, 1109.0) 701.0 (413.0, 1319.0) 821.5 (379.5, 1434.0) 0.73
Mean arterial pressure, mm Hg 607 89.8 (83.7, 97.8) 89.9 (84.2, 99.8) 90.8 (84.5, 100.0) 95 (87.7, 104.8) 0.01∗
CRP, mg/L 600 1.3 (0.5, 2.9) 1.3 (0.6, 3.7) 1.8 (0.7, 4.3) 2.5 (0.9, 4.6) 0.008∗
ALT, U/L4 284 19.0 (16.0, 24.0) 18.0 (15.0, 29.0) 21.0 (16.0, 25.0) 19.0 (17.0, 28.0) 0.22
AST, U/L4 283 29.0 (24.0, 34.0) 25.0 (21.0, 33.0) 29.0 (24.0, 35.0) 28.0 (24.0, 35.0) 0.15
AST:ALT ratio4 283 1.6 (1.2, 1.8) 1.4 (1.0, 1.6) 1.4 (1.2, 1.7) 1.4 (1.2, 1.7) 0.049∗
Liver fat, %4,5 280 2.6 (1.9, 5.3) 2.6 (1.7, 6.2) 3.7 (2.2, 7.3) 4.3 (2.2, 7.3) 0.04∗
GGT, U/L4 286 17.0 (13.0, 26.0) 18.0 (12.0, 38.0) 19.0 (13.0, 28.0) 22.0 (14.0, 35.0) 0.44
Bilirubin, mg/dL4 285 0.3 (0.3, 0.6) 0.4 (0.3, 0.5) 0.4 (0.3, 0.5) 0.3 (0.3, 0.4) 0.67
Binary outcomes at follow-up (2012–2014)6
Hyperglycemia 603 11 (5.6) 7 (8.0) 31 (14.5) 13 (14.9) 0.01∗
Type 2 diabetes 607 39 (19.8) 20 (22.7) 68 (31.8) 28 (32.2) 0.02∗
Hypertriglyceridemia 601 13 (6.6) 4 (4.6) 22 (10.3) 12 (13.8) 0.08
Obesity 606 48 (24.4) 36 (40.9) 93 (43.5) 54 (62.1) <0.001∗
Elevated ALT 4 284 40 (50.6) 18 (46.2) 62 (62.0) 34 (58.6) 0.23
Elevated AST:ALT ratio4 284 14 (17.7) 2 (5.1) 10 (10.0) 7 (12.1) 0.20
Elevated liver fat score4,7 280 25 (31.7) 16 (41.0) 48 (48.0) 32 (55.2) 0.03∗
1Data presented as mean (SD), median (IQR), or n (%), as applicable. All values are unadjusted. ∗Statistical significance, P < 0.05. ALT, alanine aminotransferase; AST,
aspartate aminotransferase; CRP, C-reactive protein; fs, fasting serum; GGT, γ -glutamyltransferase; HOMA-B, homeostatic model assessment for β-cell function; T2DM, type 2
diabetes mellitus.
2Outcomes not shown for the 28 women missing artificially sweetened beverage intake at follow-up.
3P values for parametric continuous variables calculated using ANOVA; P values for nonparametric continuous variables calculated using Wilcoxon 2-sample test statistic;
and P values for categorical variables calculated using chi-square test statistic or Fisher’s exact test, as applicable.
4Outcomes related to liver function exclude women with habitual alcohol intake at follow-up of >24 g/d, approximately equivalent to 2 standard drinks/d.
5Calculated liver fat % = 10(−0.805 + 0.282 × metabolic syndrome (yes = 1; no = 0) + 0.078 × T2DM (yes = 2; no = 0) + 0.525 × log(fs-insulin [mU/L]) + 0.521 × log(fs-AST [U/L]) – 0.454 × log(AST/ALT)).
6The following definitions were used for the binary outcomes: elevated ALT, ≥19.0 U/L; elevated AST:ALT ratio, ratio ≥2; elevated liver fat score, > −0.640;
hypertriglyceridemia, triglycerides ≥200 mg/dL; hyperglycemia, fasting glucose ≥7.0 mmol/L; type 2 diabetes, HbA1c ≥6.5%, fasting glucose ≥7.0 mmol/L, or 2-h oral glucose
tolerance test glucose ≥11.1 mmol/L or self-report of physician diagnosis; obesity, BMI ≥30.0.
7Liver fat score = −2.89 + 1.18 × metabolic syndrome (yes = 1/no = 0) + 0.45 × T2DM (yes = 2/no = 0) + insulin (mU/L) + 0.04 × AST (U/L) – 0.94 × AST/ALT.
the same direction as the overall findings (Supplemental Tables
8 and 9).
Discussion
Using data collected at 2 time points 9–16 y apart among
women with a history of GDM, we examined associations
between ASB consumption and a comprehensive panel of
cardiometabolic markers and clinical outcomes. After careful
consideration for reverse causality and confounding, we found
that ASB consumption was not significantly associated with
either beneficial or detrimental cardiometabolic profiles in this
sample of high-risk women. We observed that consumers of
ASBs have an overall unfavorable cardiometabolic profile;
however, this was largely attributable to existing adiposity at
baseline, with the possible exception of an adverse impact on
glucose homeostasis. Specifically, we observed that ASB intake
was significantly associated with a small increase in HbA1c
levels, particularly among women with normal prepregnancy
weight, but these findings became statistically insignificant in
sensitivity analyses to rule out the possibility of reverse causation.
Furthermore, some adverse associations were observed with low
levels of consumption, but the signals were not consistent across
exposure time periods. Thus, the lack of consistent findings after
accounting for other risk factors indicates that there were likely
no adverse or favorable associations between ASB intake and
cardiometabolic health among women with a history of GDM.
Women with a history of GDM have an exceptionally high risk
for developing T2DM and other cardiometabolic complications
later in life. Prior observational studies reported adherence to
healthful dietary patterns was associated with a lower risk of
progression from GDM to T2DM (36), yet there has been limited
research on beverage intake in this high-risk population. We
found that ∼30% of the women in our study were regularly
consuming ASBs during pregnancy, which is much higher than
in the general DNBC cohort and estimates for all US pregnant
women during a similar period (19, 37), likely due to the fact
that all women in our study had GDM during their pregnancy.
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TABLE 4 Consumption of artificially sweetened beverages during pregnancy and adjusted associations with cardiometabolic outcomes 9–16 y later among
women with a history of gestational diabetes1
Artificially sweetened beverage intake in pregnancy (1996–2002)
n <1 serving/mo 1–4 servings/mo 2–6 servings/wk ≥1 servings/d P-trend
Continuous outcomes (2012–2014)2
HbA1c 603 0.0 (Reference) 2.2 (−1.6, 6.1) 3.0 (0.3, 5.9)∗ 4.2 (0.2, 8.3)∗ 0.06
Fasting glucose 603 0.0 (Reference) 0.6 (−6.6, 8.5) 3.2 (−1.3, 8.0) 4.0 (−2.4, 10.8) 0.24
Fasting insulin 600 0.0 (Reference) 21.1 (4.3, 40.7)∗ 10.8 (−3.4, 27.0) 9.2 (−8.1, 29.8) 0.58
C-peptide 601 0.0 (Reference) 14.8 (3.2, 27.6)∗ 1.7 (−7.1, 11.4) 0.0 (−10.9, 12.2) 0.62
HOMA-IR 599 0.0 (Reference) 24.5 (6.0, 46.1)∗ 13.6 (−2.1, 31.8) 11.7 (−6.8, 33.9) 0.48
HOMA-B 599 0.0 (Reference) 15.3 (−3.8, 38.3) 4.3 (−10.2, 21.1) 2.2 (−16.9, 25.7) 0.94
Triglycerides 601 0.0 (Reference) 10.4 (−1.3, 23.6) 4.5 (−4.9, 14.9) 4.5 (−7.6, 18.1) 0.71
HDL 601 0.0 (Reference) 0.2 (−5.6, 6.4) − 1.5 (−6.4, 3.7) − 1.1 (−6.9, 5.2) 0.72
LDL 592 0.0 (Reference) − 0.2 (−8.2, 8.6) 1.0 (−5.6, 8.0) − 3.9 (−11.8, 4.6) 0.34
BMI 606 0.0 (Reference) 1.5 (−1.9, 5.1) 2.7 (−0.4, 5.9) 1.0 (−2.9, 5.0) 0.79
Waist circumference 606 0.0 (Reference) 2.0 (−0.5, 4.5) 2.6 (0.3, 4.9)∗ 1.6 (−1.1, 4.5) 0.40
Visceral adipose tissue 192 0.0 (Reference) 27.6 (−14.4, 90.3) 15.9 (−16.7, 61.4) 18.7 (−20.7, 77.7) 0.54
Mean arterial pressure 607 0.0 (Reference) 1.1 (−1.8, 4.2) − 0.6 (−3.2, 2.0) − 0.8 (−3.6, 2.2) 0.51
CRP 600 0.0 (Reference) 17.6 (−13.5, 60.0) 19.4 (−7.7, 54.3) 9.9 (−17.5, 46.4) 0.70
ALT3 284 0.0 (Reference) 3.7 (−11.1, 21.0) 8.7 (−6.4, 26.2) − 1.7 (−17.1, 16.5) 0.69
AST3 283 0.0 (Reference) 6.0 (−6.7, 20.5) 4.6 (−6.5, 17.0) − 0.0 (−11.6, 13.1) 0.80
AST:ALT ratio3 283 0.0 (Reference) 3.8 (−8.3, 17.4) − 3.7 (−12.7, 6.1) 1.6 (−9.8, 14.4) 0.82
Liver fat %3,4 280 0.0 (Reference) 13.4 (−11.7, 45.5) 21.2 (−0.9, 48.3) 14.6 (−10.9, 47.3) 0.42
GGT3 286 0.0 (Reference) 3.0 (−18.9, 30.7) 8.8 (−11.2, 33.4) 13.6 (–11.0, 44.8) 0.33
Bilirubin3 285 0.0 (Reference) − 4.1 (–22.0, 17.9) − 11.9 (−23.6, 1.6) − 3.3 (−19.1, 15.6) 0.87
Binary outcomes (2012–2014)5
Hyperglycemia 603 1.00 (Reference) 1.49 (0.73, 3.04) 1.31 (0.70, 2.43) 1.22 (0.56, 2.66) 0.82
Type 2 diabetes 607 1.00 (Reference) 1.29 (0.85, 1.94) 1.11 (0.77, 1.59) 1.17 (0.77, 1.77) 0.63
Hypertriglyceridemia 601 1.00 (Reference) 2.50 (1.27, 4.90)∗ 1.21 (0.57, 2.56) 1.13 (0.49, 2.63) 0.72
Obesity 606 1.00 (Reference) 1.20 (0.87, 1.64) 1.43 (1.13, 1.82)∗ 1.18 (0.89, 1.57) 0.50
Elevated ALT3 284 1.00 (Reference) 0.92 (0.64, 1.33) 1.06 (0.79, 1.41) 1.05 (0.77, 1.43) 0.70
Elevated AST:ALT ratio3 284 1.00 (Reference) 1.39 (0.53, 3.61) 0.59 (0.22, 1.60) 1.13 (0.43, 2.96) 0.85
Elevated liver fat score3,6 280 1.00 (Reference) 1.20 (0.76, 1.89) 1.24 (0.87, 1.77) 1.22 (0.83, 1.81) 0.43
1Analyses adjusted for index pregnancy characteristics, including maternal age, prepregnancy BMI, parity, education, smoking, prepregnancy chronic diseases,
moderate/vigorous physical activity, Alternative Healthy Eating Index–2010, intake of tea, and intake of coffee. Multiple imputation with 20 replicates was used for missing
exposure and covariate data. ∗Statistical significance, P < 0.05. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; fs, fasting serum; GGT,
γ -glutamyltransferase; HOMA-B, homeostatic model assessment for β-cell function; T2DM, type 2 diabetes mellitus.
2Continuous outcomes were log-transformed. Results are presented as the percentage difference (95% CI) calculated as the exponentiated β coefficient from the adjusted
linear regression model, subtracting 1 and multiplying by 100.
3Outcomes related to liver function exclude women with habitual alcohol intake at follow-up of >24 g/d, approximately equivalent to 2 standard drinks/d.
4Calculated liver fat % = 10(−0.805 + 0.282 × metabolic syndrome (yes = 1; no = 0) + 0.078 × T2DM (yes = 2; no = 0) + 0.525 × log(fs-insulin [mU/L]) + 0.521 × log(fs-AST [U/L]) – 0.454 × log(AST/ALT)).
5Binary outcomes are presented as RR (95% CI) calculated from a Poisson regression model with robust error variance. The following definitions were used for the binary
outcomes: elevated ALT, ≥19.0 U/L; elevated AST:ALT ratio, ratio ≥2; liver fat score, > −0.640; hypertriglyceridemia, triglycerides ≥200 mg/dL; hyperglycemia, fasting glucose
≥7.0 mmol/L; type 2 diabetes, HbA1c ≥6.5%, fasting glucose ≥7.0 mmol/L, or 2-h oral glucose tolerance test glucose ≥11.1 mmol/L or self-report of physician diagnosis; obesity,
BMI ≥30.0.
6Liver fat score = −2.89 + 1.18 × metabolic syndrome (yes = 1/no = 0) + 0.45 × T2DM (yes = 2/no = 0) + insulin (mU/L) + 0.04 × AST (U/L) – 0.94 ×AST/ALT.
At follow-up 9–16 y later, ∼36% were regular consumers.
Notably, however, the amount that consumers were drinking was
relatively low, with themajority of women consuming<1 serving
per day. ASB consumption was strongly associated with less
sugar-sweetened beverage intake, higher BMI prior to the index
pregnancy and at follow-up, as well as prevalent chronic diseases
at follow-up, which suggests that ASB intake may be a marker of
high-risk women and thus the need for careful consideration of
reverse causality.
Findings frommany, but not all, animal studies have suggested
an adverse association between high levels of ASBs and glucose
intolerance, insulin resistance, and obesity (4, 38, 39). Yet,
data in humans are conflicting. Observational studies have been
mixed, with both beneficial and adverse associations observed
between ASB intake and adiposity, metabolic syndrome, and
T2DM; however, positive associations are largely confounded
by reverse causality and attenuated with adjustment for BMI
(4, 5, 7). Clinical trials tend to suggest either no effect or no
beneficial effects on body weight with short-term replacement of
sugar-sweetened beverages with ASBs, yet long-term evidence
is lacking (4–6). Therefore, current recommendations for ASB
intake are generally cautious given the limited evidence base;
they suggest that ASBs can be used to reduce added sugar intake
from sugar-sweetened beverages, particularly among individuals
with diabetes, with the caveat that compensation with additional
calories does not take place (2).
A major concern with observational studies on ASB con-
sumption is confounding and reverse causality. For example,
individuals who choose to drink ASBs may have switched from
sugar-sweetened beverages given the historical perspective that
ASBs were a benign low-calorie beverage option (36). We
observed in our data that prepregnancy BMI was strongly and
positively associated with ASB intake during pregnancy. Without
adjustment for prepregnancy BMI, we would have observed an
unfavorable cardiometabolic profile associated with ASB intake.
Even after adjustment, we observed some positive associations
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TABLE 5 Consumption of artificially sweetened beverages during the past year and adjusted associations with cardiometabolic outcomes among women
with a history of gestational diabetes1
Habitual artificially sweetened beverage intake at follow-up (2012–2014)
n <1 serving/mo 1–4 servings/mo 2–6 servings/wk ≥1 servings/d P-trend
Continuous outcomes
(2012–2014)2
HbA1c 603 0.0 (Reference) − 0.7 (−3.3, 1.9) 3.0 (0.6, 5.5)∗ 6.5 (1.9, 11.3)∗ 0.007∗
Fasting glucose 603 0.0 (Reference) 0.6 (−3.1, 4.4) 4.5 (0.2, 9.1)∗ 7.0 (−0.4, 14.9) 0.11
Fasting insulin 600 0.0 (Reference) 6.8 (−6.9, 22.5) − 3.0 (−14.4, 9.9) − 7.8 (−26.0, 14.9) 0.39
C-peptide 601 0.0 (Reference) 4.1 (−5.2, 14.4) − 2.9 (−10.7, 5.7) − 7.5 (−19.2, 5.9) 0.20
HOMA-IR 599 0.0 (Reference) 7.4 (−7.5, 24.8) 2.4 (−10.4, 17.0) − 1.1 (−20.5, 22.9) 0.74
HOMA-B 599 0.0 (Reference) 4.3 (−9.3, 19.9) − 13.7 (−24.8, −1.0)∗ − 18.9 (−38.6, 7.1) 0.17
Triglycerides 601 0.0 (Reference) − 2.2 (−11.3, 7.9) 4.2 (−4.7, 14.0) 5.8 (−8.1, 21.9) 0.44
HDL 601 0.0 (Reference) 2.7 (−2.9, 8.6) 1.3 (−3.6, 6.4) 1.1 (−6.0, 8.7) 0.97
LDL 592 0.0 (Reference) − 5.6 (−12.2, 1.5) − 4.1 (−9.7, 1.8) − 1.8 (−9.8, 6.8) 0.89
BMI 606 0.0 (Reference) 3.0 (−0.2, 6.2) 0.8 (−2.2, 4.0) 2.5 (−2.8, 8.2) 0.52
Waist circumference 606 0.0 (Reference) 2.9 (0.3, 5.6)∗ 0.3 (−1.7, 2.4) 1.1 (−1.8, 4.2) 0.79
Visceral adipose tissue 192 0.0 (Reference) 10.4 (−21.7, 55.7) 4.4 (−22.6, 40.8) − 7.4 (−37.5, 37.4) 0.55
Mean arterial pressure 607 0.0 (Reference) 0.3 (−2.6, 3.2) − 0.4 (−2.6, 1.9) 2.6 (−0.9, 6.1) 0.11
CRP 600 0.0 (Reference) − 5.8 (−29.3, 25.5) − 6.4 (−25.4, 17.4) − 9.8 (−33.7, 22.7) 0.61
ALT3 284 0.0 (Reference) 2.6 (−12.7, 20.5) 8.2 (−4.8, 22.9) 2.4 (−12.4, 19.8) 0.94
AST3 283 0.0 (Reference) − 10.8 (−21.3, 1.2) − 2.1 (−10.8, 7.5) − 3.9 (−14.9, 8.5) 0.90
AST:ALT ratio3 283 0.0 (Reference) − 13.2 (−22.7, −2.5)∗ − 9.2 (−17.0, −0.6)∗ − 6.4 (−16.3, 4.8) 0.92
Liver fat %3,4 280 0.0 (Reference) − 6.4 (−26.3, 18.7) 10.7 (−8.8, 34.3) − 1.0 (−23.5, 28.1) 0.84
GGT3 286 0.0 (Reference) 8.9 (−18.5, 45.7) − 4.5 (−20.4, 14.6) 4.7 (−16.4, 31.2) 0.69
Bilirubin3 285 0.0 (Reference) 7.0 (−11.2, 29.0) 5.2 (−8.7, 21.2) − 4.0 (−18.4, 13.0) 0.31
Binary outcomes (2012–2014)5
Hyperglycemia 603 1.00 (Reference) 1.12 (0.47, 2.69) 1.80 (0.95, 3.42) 1.69 (0.74, 3.83) 0.41
Type 2 diabetes 607 1.00 (Reference) 1.03 (0.65, 1.65) 1.34 (0.95, 1.91) 1.13 (0.75, 1.71) 0.94
Hypertriglyceridemia 601 1.00 (Reference) 0.66 (0.21, 2.05) 1.33 (0.67, 2.62) 1.31 (0.57, 3.01) 0.50
Obesity 606 1.00 (Reference) 1.25 (0.91, 1.70) 1.21 (0.93, 1.57) 1.29 (0.95, 1.74) 0.26
Elevated ALT3 284 1.00 (Reference) 0.87 (0.59, 1.30) 1.17 (0.89, 1.53) 1.05 (0.77, 1.45) 0.83
Elevated AST:ALT ratio3 284 1.00 (Reference) 0.29 (0.07, 1.15) 0.51 (0.24, 1.08) 0.74 (0.29, 1.89) 0.86
Elevated liver fat score3,6 280 1.00 (Reference) 1.11 (0.69, 1.78) 1.39 (0.96, 2.00) 1.29 (0.87, 1.93) 0.43
1Analyses adjusted for current characteristics, including maternal age, parity, education, smoking, moderate/vigorous physical activity, Alternative Healthy Eating
Index–2010, intake of tea, intake of coffee, and prepregnancy chronic diseases at the index pregnancy. Multiple imputation with 20 replicates was used for missing exposure and
covariate data. ∗Statistical significance, P < 0.05. ALT, alanine aminotransferase; AST, aspartate aminotransferase; fs, fasting serum; GGT, γ -glutamyltransferase; HOMA-B,
homeostatic model assessment for β-cell function; T2DM, type 2 diabetes mellitus.
2Continuous outcomes were log-transformed. Results are presented as the percentage difference (95% CI) calculated as the exponentiated β coefficient from the adjusted
model, subtracting 1 and multiplying by 100.
3Outcomes related to liver function exclude women with habitual alcohol intake >24 g/d, approximately equivalent to 2 standard drinks/d.
4Calculated liver fat % = 10(−0.805 + 0.282 × metabolic syndrome (yes = 1; no = 0) + 0.078 × T2DM (yes = 2; no = 0) + 0.525 × log(fs-insulin [mU/L]) + 0.521 × log(fs-AST [U/L]) – 0.454 × log(AST/ALT)).
5Binary outcomes are presented as RR (95% CI). The following definitions were used for the binary outcomes: elevated ALT, ≥19.0 U/L; elevated AST:ALT ratio, ratio ≥2;
liver fat score, > −0.640; hypertriglyceridemia, triglycerides ≥200 mg/dL; hyperglycemia, fasting glucose ≥7.0 mmol/L; type 2 diabetes, HbA1C ≥6.5%, fasting glucose ≥7.0
mmol/L, or 2-h oral glucose tolerance test glucose ≥11.1 mmol/L or self-report of physician diagnosis; obesity, BMI ≥30.0.
6Liver fat score = −2.89 + 1.18 × metabolic syndrome (yes = 1/no = 0) + 0.45 × T2DM (yes = 2/no = 0) + insulin (mU/L) + 0.04 × AST (U/L) – 0.94 × AST/ALT.
with HbA1c and fasting glucose levels. However, with further
consideration of reverse causality, particularly that the HbA1c
findings were null among women with prepregnancy overweight
or obesity, we suggest that ASBs are not associated with any
of the studied cardiometabolic outcomes among women with a
history of GDM.
To provide a more complete assessment of ASB intake, our
analysis included a wide range of cardiometabolic outcomes
across various domains. Associations between ASB intake and
cardiometabolic health are biologically plausible given the wide
array of systems that either have sweet taste (or similarly
structured) receptors or have metabolic actions downstream of
these pathways (8). A large cohort study examined components
of metabolic syndrome and similarly observed null findings with
blood pressure, HDL cholesterol, or triglycerides; significant
associations with waist circumference and fasting glucose were
observed, but these associations were not adjusted for baseline
BMI (40). We also examined the outcome of fatty liver using
previously validated liver fat scores (27). After adjustment for
baseline BMI, we did not observe any significant findings with
any liver outcome, which is consistent with the 1 prior study
on ASBs and liver disease (41). The reporting of these null
associations acrossmultiple systems in the current study indicates
that there are not overlooked pathways potentially affected by
ASB intake and provides some of the first data in the high-
risk population of women with prior GDM for whom informed
recommendations are critically important.
Major strengths of our study are the use of prospective
data and robust sensitivity analyses to reduce the potential for
reverse causation. In addition, the wide range of outcomes
in the study were assessed at a clinical exam performed
according to a standard protocol. Furthermore, our follow-up
data of 9–16 y adds to the literature on the potential long-
term impacts of ASB consumption. One potential limitation
of our study is that we utilized prepregnancy BMI to adjust
for baseline BMI. Prepregnancy BMI was calculated from self-
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TABLE 6 Long-term consumption patterns of artificially sweetened beverages from pregnancy 9–16 y earlier to the past year and adjusted associations with
current cardiometabolic outcomes among women with a history of gestational diabetes1
Habitual artificially sweetened beverage intake
n
≤4 servings/mo in pregnancy
and at follow-up
≤4 servings/mo in pregnancy
and ≥2 servings/wk at
follow-up
≥2 servings/wk in pregnancy
and ≤4 servings/mo at
follow-up
≥2 serving/wk in pregnancy
and at follow-up
Continuous outcomes (2012–2014)2
HbA1c 603 0.0 (Reference) 4.3 (1.3, 7.4)∗ 3.0 (−0.1, 6.1) 6.0 (2.8, 9.1)∗
Fasting glucose 603 0.0 (Reference) 3.5 (−2.2, 9.4) 1.5 (−2.7, 5.9) 7.1 (2.2,12.4)∗
Fasting insulin 600 0.0 (Reference) − 6.4 (−20.9, 10.8) 8.6 (−8.2, 28.5) − 1.6 (−14.8, 13.7)
C-peptide 601 0.0 (Reference) − 2.7 (−12.5, 8.2) 1.3 (−10.0, 14.1) − 6.8 (−15.1, 2.4)
HOMA-IR 599 0.0 (Reference) − 0.5 (−16.1, 18.1) 10.5 (−8.3, 33.3) 4.7 (−10.3, 22.2)
HOMA-B 599 0.0 (Reference) − 16.9 (−31.9, 1.4) 3.1 (−11.8, 20.5) − 14.3 (−27.3, 1.1)
Triglycerides 601 0.0 (Reference) 10.7 (0.0, 22.5) 6.3 (−5.0, 19.0) 5.2 (−4.9, 16.4)
HDL 601 0.0 (Reference) − 0.6 (−6.6, 5.7) − 2.8 (−9.0, 3.9) − 0.6 (−5.8, 5.0)
LDL 592 0.0 (Reference) − 1.7 (−8.2, 5.2) − 0.7 (−9.2, 8.7) − 2.0 (−8.5, 4.9)
BMI 606 0.0 (Reference) 1.5 (−2.7, 5.9) 3.5 (−0.2, 7.3) 1.5 (−1.7, 4.8)
Waist circumference 606 0.0 (Reference) − 0.8 (−3.2, 1.6) 1.7 (−1.4, 4.9) 1.0 (−1.2, 3.3)
Visceral adipose tissue 192 0.0 (Reference) − 0.2 (−30.8, 43.7) 13.6 (−25.0, 72.1) 3.7 (−26.4, 46.2)
Mean arterial pressure 607 0.0 (Reference) 0.2 (−2.6, 3.0) − 1.4 (−4.6, 1.9) − 0.5 (−3.0, 2.1)
CRP 600 0.0 (Reference) − 2.7 (−26.6, 28.9) 21.0 (−11.3, 65.1) 3.5 (−19.8, 33.5)
ALT3 284 0.0 (Reference) 8.9 (−5.7, 25.7) 6.0 (−15.3, 32.5) 6.5 (−8.4, 24.0)
AST3 283 0.0 (Reference) 2.4 (−8.4, 14.5) 1.8 (−12.8, 19.0) 1.5 (−9.1, 13.4)
AST:ALT ratio3 283 0.0 (Reference) − 5.3 (−15.3, 5.8) − 3.9 (−16.6, 10.6) − 4.8 (−14.6, 6.0)
Liver fat %3,4 280 0.0 (Reference) 8.0 (−12.8, 33.7) 13.8 (−12.5, 48.1) 19.8 (−3.3, 48.5)
GGT3 286 0.0 (Reference) 2.6 (−17.9, 28.2) 20.1 (−12.8, 65.4) 3.0 (−16.4, 27.0)
Bilirubin3 285 0.0 (Reference) − 3.5 (−18.0, 13.6) − 14.2 (−28.9, 3.4) − 8.5 (−21.3, 6.4)
Binary outcomes (2012–2014)5
Hyperglycemia 603 1.00 (Reference) 1.86 (0.92, 3.78) 1.20 (0.45, 3.21) 1.80 (0.86, 3.75)
Type 2 diabetes 607 1.00 (Reference) 1.32 (0.90, 1.92) 1.08 (0.65, 1.77) 1.28 (0.88, 1.87)
Hypertriglyceridemia 601 1.00 (Reference) 1.77 (0.82, 3.78) 0.92 (0.34, 2.45) 1.23 (0.56, 2.68)
Obesity 606 1.00 (Reference) 1.18 (0.88, 1.59) 1.41 (0.98, 2.02) 1.37 (1.04, 1.81)
Elevated ALT3 284 1.00 (Reference) 1.23 (0.88, 1.72) 1.08 (0.68, 1.71) 1.21 (0.87, 1.69)
Elevated AST:ALT ratio3 284 1.00 (Reference) 0.88 (0.38, 2.04) 0.84 (0.27, 2.62) 0.62 (0.25, 1.57)
Elevated liver fat score3,6 280 1.00 (Reference) 1.37 (0.92, 2.05) 1.23 (0.73, 2.07) 1.45 (0.97, 2.15)
1Analyses adjusted for current characteristics, including maternal age, parity, education, smoking, moderate/vigorous physical activity, Alternative Healthy Eating
Index–2010, intake of tea, intake of coffee, and prepregnancy chronic diseases at the index pregnancy. Multiple imputation with 20 replicates was used for missing exposure and
covariate data. ∗Statistical significance, P < 0.05. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; fs, fasting serum; GGT,
γ -glutamyltransferase; HOMA-B, homeostatic model assessment for β-cell function; T2DM, type 2 diabetes mellitus.
2Continuous outcomes were log-transformed. Results are presented as the percentage difference (95% CI) calculated as the exponentiated β coefficient from the adjusted
model, subtracting 1 and multiplying by 100.
3Outcomes related to liver function exclude women with habitual alcohol intake >24 g/d, approximately equivalent to 2 standard drinks/d.
4Calculated liver fat % = 10(−0.805 + 0.282 × metabolic syndrome (yes = 1; no = 0) + 0.078 × T2DM (yes = 2; no = 0) + 0.525 × log(fs-insulin [mU/L]) + 0.521 × log(fs-AST [U/L]) – 0.454 × log(AST/ALT)).
5Binary outcomes are presented as RR (95% CI). The following definitions were used for the binary outcomes: elevated ALT, ≥19.0 U/L; elevated AST:ALT ratio, ratio ≥2;
liver fat score, > −0.640; hypertriglyceridemia, triglycerides ≥200 mg/dL; hyperglycemia, fasting glucose ≥7.0 mmol/L; type 2 diabetes, HbA1c ≥6.5%, fasting glucose ≥7.0
mmol/L, or 2-h oral glucose tolerance test glucose ≥11.1 mmol/L or self-report of physician diagnosis; obesity, BMI ≥30.
6Liver fat score = −2.89 + 1.18 × metabolic syndrome (yes = 1/no = 0) + 0.45 × T2DM (yes = 2/no = 0) + insulin (mU/L) + 0.04 × AST (U/L) – 0.94 × AST/ALT.
reported prepregnancy weight that was ascertained early in
pregnancy. However, self-reported prepregnancy weight is highly
correlated with measured prepregnancy weight (42). In addition,
we did not have information on the type of artificial sweeteners
in the drinks consumed by women in the study. However,
during the same time period in Denmark, carbonated beverages
usually contained a mixture of aspartame and acesulfame-K,
and noncarbonated beverages usually contained cyclamate and
saccharine (43). Cyclamate is approved in Europe but not
in the United States or Canada (8), which may impact the
generalizability of our findings beyond European women with
prior GDM. Furthermore, we do not have data on food products
containing nonnutritive sweeteners. Thus, overall consumption
of nonnutritive sweeteners is likely underestimated. Another
limitation was that we did not have data on how long women
were consuming ASBs prior to baseline (i.e., pregnancy), which
may have potentially led to obesity at baseline, in which case
adjustment for prepregnancy BMI could be an overadjustment.
Also, prior ASB intake may have contributed to the presence
of chronic diseases at follow-up; therefore, excluding these
women in sensitivity analyses could also be an overadjustment.
However, we examined consumption patterns at both time points
9–16 y apart and also consumption at follow-up among women
who were consumers at baseline, potentially indicating long-
term consumption; these results were mostly null with the
exception of HbA1C and also not robust to sensitivity analyses to
address reverse causality. Last, our sample was moderately sized,
which may have limited our power to detect true associations,
especially among the highest consumers where the levels were
quite low and for some of the select groups used for sensitivity
analyses. Nonetheless, the current study represents the largest
study among women at high risk with long-term follow-
up and a comprehensive characterization of cardiometabolic
profiles.
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In conclusion, we observed that among Danish women
with a history of GDM, a population at high risk for car-
diometabolic diseases, ASB intake was not associated with either
improvements in or worsening of cardiometabolic complications.
Although high-risk individuals are recommended to consume
ASBs instead of sugar-sweetened beverages as a means of
reducing sugar intake and risk for cardiometabolic diseases,
we did not observe significant improvements in or worsening
of cardiometabolic health with higher ASB intake in this
population.
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